Lupron Depot (leuprolide acetate for depot suspension), 11.25 mg, Lupron Depot (leuprolide acetate for depot suspension), 3.75 mg
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)
WARNINGS AND PRECAUTIONS
- Postmarketing reports of convulsions have been observed in patients on leuprolide acetate therapy. These included patients with a history of seizures, epilepsy, cerebrovascular disorders, central nervous system anomalies or tumors, and in patients on concomitant medications that have been associated with convulsions such as bupropion and SSRIs. Convulsions have also been reported in patients in the absence of any of the conditions mentioned above. Patients receiving a GnRH agonist who experience convulsion should be managed according to current clinical practice.
- Hepato-biliary disorder: Serious drug-induced liver injury
- Respiratory, thoracic and mediastinal disorder – Interstitial lung disease
- rarely reported serious liver injury